Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab Phase 2-3 Study in Japan
jRCT2080225248Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3 trial of otilimab, sponsored by GSK. Started Jun 2020; status: completed.
02
Drugs
otilimab
Beyond the preview
Go deeper on jRCT2080225248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225248.